Targeting DNA and mutant p53 by a naphthalimide derivative, NA20, exhibits selective inhibition in gastric tumorigenesis by blocking mutant p53-EGFR signaling pathway
- 1 November 2020
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 887, 173584
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Guangxi Province (2017GXNSFAA198076)
- Transformation Program of Scientific and Technological Achievements of Jiangsu Province (2019PY001)
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Ministry of Education
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China (81871636, 81960668)
This publication has 33 references indexed in Scilit:
- Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasionOncogene, 2012
- HER2 expression and its clinicopathological features in resectable gastric cancerGastric Cancer, 2012
- A Unified Model of Mammalian BCL-2 Protein Family Interactions at the MitochondriaMolecular Cell, 2011
- Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cellsOncogene, 2010
- Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor PathwayClinical Lung Cancer, 2009
- A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced MetastasisCell, 2009
- A Global Map of p53 Transcription-Factor Binding Sites in the Human GenomeCell, 2006
- TP53 and gastric carcinoma: A reviewHuman Mutation, 2003
- Helicobacter pyloriInfection and the Development of Gastric CancerNew England Journal of Medicine, 2002
- CYCLIN-DEPENDENT KINASES: Engines, Clocks, and MicroprocessorsAnnual Review of Cell and Developmental Biology, 1997